Is Dexcom (DXCM) a risky stock?
As of July 21, 2026, Clavix grades Dexcom (DXCM) A- for risk, a composite score of 80 out of 100 on an A+ to F scale, which puts DXCM in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind DXCM's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how DXCM scores on each, as of July 21, 2026.
What's moving DXCM's risk right now
Company-specific signals Clavix flags behind DXCM's current grade, drawn from recent news and filings as of July 21, 2026.
Health Canada approved the G7 15 Day CGM for adults with diabetes, and Dexcom added compatibility with Tandem's Mobi and t:slim X2 insulin pumps. Both moves widen the product's reach and could pull in more Canadian users and pump customers.
Health Canada cleared Dexcom's G7 15 Day for sale, letting it compete in Canada with a longer-wear sensor than rivals. A separate promotional push highlights the sensor working with Insulet's Omnipod 5 pump, reinforcing the connected-device story.
Mizuho set a new $90 price target on Dexcom, up roughly 5.9% from the prior level, signaling more rating confidence in the stock's near-term path. The target reflects Mizuho's view that Dexcom is positioned to outperform.
What a A- grade means
On the Clavix A+ to F scale, DXCM's composite of 80 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell DXCM or any security. Grades are risk indicators, not predictions of return. Data may be delayed.